Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed [Yahoo! Finance]
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Yahoo! Finance
alveolar proteinosis, granting Priority Review with a PDUFA action date of August 22, 2026. This filing adds to MOLBREEVI's existing Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations, underscoring its potential importance for a rare respiratory disease with limited treatment options. We'll now examine how the FDA's Priority Review decision for MOLBREEVI shapes Savara's investment narrative over the coming months. Find 47 companies with promising cash flow potential yet trading below their fair value What Is Savara's Investment Narrative? To own Savara today, you really have to believe that MOLBREEVI can evolve from a single late-stage asset into a commercially meaningful rare-disease franchise, without the company running out of financial runway along the way. The FDA's Priority Review of the BLA, with an August 22, 2026 PDUFA date, now becomes the clear anchor for the story and effectively pulls regulatory tim
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Announces Participation in 2026 Citizens Life Sciences ConferenceBusiness Wire
- Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]Yahoo! Finance
- Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Business Wire
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesBusiness Wire
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- SVRA's page on the SEC website